Vertex Pharmaceuticals (VRTX)
(Delayed Data from NSDQ)
$494.46 USD
-11.32 (-2.24%)
Updated Aug 2, 2024 04:00 PM ET
After-Market: $494.52 +0.06 (0.01%) 7:58 PM ET
4-Sell of 5 4
D Value B Growth F Momentum D VGM
Brokerage Reports
0 items in cart
Vertex Pharmaceuticals Incorporated [VRTX]
Reports for Purchase
Showing records 301 - 320 ( 331 total )
Company: Vertex Pharmaceuticals Incorporated
Industry: Medical - Biomedical and Genetics
Company: Vertex Pharmaceuticals Incorporated
Industry: Medical - Biomedical and Genetics
Company: Vertex Pharmaceuticals Incorporated
Industry: Medical - Biomedical and Genetics
Company: Vertex Pharmaceuticals Incorporated
Industry: Medical - Biomedical and Genetics
Company: Vertex Pharmaceuticals Incorporated
Industry: Medical - Biomedical and Genetics
Upcoming Events for the Week of October 24
Provider: WEDBUSH SECURITIES INC.
Company: Vertex Pharmaceuticals Incorporated
Industry: Medical - Biomedical and Genetics
Company: Vertex Pharmaceuticals Incorporated
Industry: Medical - Biomedical and Genetics
Initiating Coverage with a Buy Rating and Price Target of $45
Provider: DAWSON JAMES SECURITIES, INC.
Analyst: BERNARDINO V
Company: Vertex Pharmaceuticals Incorporated
Industry: Medical - Biomedical and Genetics
Company: Vertex Pharmaceuticals Incorporated
Industry: Medical - Biomedical and Genetics
Company: Vertex Pharmaceuticals Incorporated
Industry: Medical - Biomedical and Genetics
Company: Vertex Pharmaceuticals Incorporated
Industry: Medical - Biomedical and Genetics
2010 AASLD Abstract Titles Review - Second Wave Including Late-Breakers
Provider: WEDBUSH SECURITIES INC.
Analyst: XU Y
Company: Vertex Pharmaceuticals Incorporated
Industry: Medical - Biomedical and Genetics
The Week Ahead in Life Sciences
Provider: WEDBUSH SECURITIES INC.
Company: Vertex Pharmaceuticals Incorporated
Industry: Medical - Biomedical and Genetics
Boceprevir Topline May Be a Temporary Relief to Vertex
Provider: WEDBUSH SECURITIES INC.
Analyst: XU Y
Company: Vertex Pharmaceuticals Incorporated
Industry: Medical - Biomedical and Genetics
Biotechnology / Biopharmaceuticals -2010 AASLD Abstract Titles Review - First Wave Without Late Breakers
Provider: WEDBUSH SECURITIES INC.
Analyst: XU Y
Company: Vertex Pharmaceuticals Incorporated
Industry: Medical - Biomedical and Genetics
Lowering PT to $40 on Anticipated Stronger Competition
Provider: WEDBUSH SECURITIES INC.
Analyst: XU Y
Company: Vertex Pharmaceuticals Incorporated
Industry: Medical - Biomedical and Genetics
The Week Ahead in Life Sciences
Provider: WEDBUSH SECURITIES INC.
Company: Vertex Pharmaceuticals Incorporated
Industry: Medical - Biomedical and Genetics
Interim TMC435 Data Impressive; Remains a Strong Competitor to Telaprevir Although >2 Years Behind
Provider: WEDBUSH SECURITIES INC.
Analyst: XU Y
Company: Vertex Pharmaceuticals Incorporated
Industry: Medical - Biomedical and Genetics
The Week Ahead in Life Sciences
Provider: WEDBUSH SECURITIES INC.
Company: Vertex Pharmaceuticals Incorporated
Industry: Medical - Biomedical and Genetics
Company: Vertex Pharmaceuticals Incorporated
Industry: Medical - Biomedical and Genetics
The Week Ahead in Life Sciences
Provider: WEDBUSH SECURITIES INC.